aap is granted European patent for silver coating technology
(Thomson Reuters ONE) -
aap Implantate AG /
aap is granted European patent for silver coating technology
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE), a developer, manufacturer, and distributor of
innovative trauma products and biomaterials, announced that the European Patent
Office recently granted it an important patent for its silver coating technology
for medical implants.
The European patent (EP 2 437 798 B1) protects both the multifunctional
antibacterial silver coating developed by the company for implants and relevant
medical tools and the method as well as apparatuses for the production of such a
coating. In a next step the European patent will be nationalized in many key
European markets and published in different languages. After the company was
granted a patent for the silver coating technology last year by the US Patent
and Trademark Office (USPTO) and has this year already been granted further
European patents for its LOQTEQ® and magnesium technology, the patent now
granted represents an important further expansion of the IP portfolio.
The fundamental added value of the silver coating technology lies in the
antibacterial property of silver. When using medical implants a biofilm can grow
on the surface, in which multi-resistant bacteria and germs are embedded. As a
consequence infections can be caused. Silver can prevent the formation of such a
biofilm leading to a potential reduction in the number of infections and
reoperations. Silver coating technology can thereby make a decisive contribution
to improving patient care and reducing healthcare costs. Overall, the silver
coating technology is not limited to use solely with aap Implantate AG's
existing portfolio; it can also be used for other orthopaedic implants and
surgical instruments. The company plans the submission of the CE approval
application for the first silver coated products in the second half of 2015.
About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that are
used in orthopedic procedures. The Company's products, which include a full line
of plating systems, cannulated screws and bone cement products, are primarily
used in the orthopedic specialty areas of trauma and spine repair. The Company's
products are sold through its direct sales force, distribution partners and
license agreements with OEM partners. aap's stock is listed in the Prime
Standard segment of the Frankfurt Stock Exchange. For more information, please
visit www.aap.de, or download the Company's investor relations app from the
Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
For inquiries please contact: aap Implantate AG, Fabian Franke, Investor
Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke(at)aap.de
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via GlobeNewswire
[HUG#1912170]
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2015 - 08:30 Uhr
Sprache: Deutsch
News-ID 386794
Anzahl Zeichen: 4951
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 208 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap is granted European patent for silver coating technology"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
